{
  "ticker": "IIQ",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02969071",
  "id": "02969071",
  "pages": 33,
  "price_sensitive": true,
  "date": "20250714",
  "time": "1518",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250714/pdf/06ls7w9g4674yq.pdf",
  "summary": "### Summary of ASX Announcement (INOVIQ - Investor Briefing)  \n\n#### **Key Operational & Financial Highlights**  \n- **Market Cap**: A$41.9m | **Cash (31 Mar 2025)**: A$8.01m  \n- **Key Pipeline Developments**:  \n  - **EXO-OC (Ovarian Cancer Diagnostic)**:  \n    - Clinical validation results: 77% sensitivity (all stages), 100% sensitivity (Stage I/II), >99.6% specificity.  \n    - Planned: Partnering for LDT commercialization (2H25) and IVD development (2026).  \n  - **CAR-Exosome Therapeutic (EEV-001)**:  \n    - Preclinical data: 88% tumor cell kill rate (TNBC/NSCLC in vitro).  \n    - Next steps: In vivo mouse model data (2H25), IND-enabling studies.  \n- **EXO-NET (Research Tool)**: 60+ pre-launch customers; targeting >200% growth in FY26.  \n\n#### **Catalysts (FY26)**  \n- EXO-OC LDT partner signing and IVD regulatory submissions.  \n- CAR-Exosome in vivo data and IND preparation.  \n- NeuCA15-3 (Breast Cancer) partnering.  \n\n#### **Strategic Focus**  \n- Dual-path commercial strategy (LDT fast-track + IVD approval) for EXO-OC in $5.5B ovarian cancer Dx market.  \n- CAR-Exosome therapy positioned as lower-cost alternative to CAR-T (TNBC focus).  \n\n**No capital raising or material financial changes announced.**",
  "usage": {
    "prompt_tokens": 8877,
    "completion_tokens": 345,
    "total_tokens": 9222,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-14T05:34:07.304379"
}